|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1996-8-8
|
|
pubmed:abstractText |
To preliminarily evaluate the safety and efficacy of different dose levels and dosing frequencies of recombinant human interleukin-1 receptor antagonist (rHuIL-1Ra) in the treatment of patients with rheumatoid arthritis (RA).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1092-101
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8670316-Antibodies,
pubmed-meshheading:8670316-Arthritis, Rheumatoid,
pubmed-meshheading:8670316-Double-Blind Method,
pubmed-meshheading:8670316-Drug Administration Schedule,
pubmed-meshheading:8670316-Female,
pubmed-meshheading:8670316-Humans,
pubmed-meshheading:8670316-Injections, Subcutaneous,
pubmed-meshheading:8670316-Interleukin 1 Receptor Antagonist Protein,
pubmed-meshheading:8670316-Male,
pubmed-meshheading:8670316-Middle Aged,
pubmed-meshheading:8670316-Quality of Life,
pubmed-meshheading:8670316-Receptors, Interleukin-1,
pubmed-meshheading:8670316-Recombinant Proteins,
pubmed-meshheading:8670316-Severity of Illness Index,
pubmed-meshheading:8670316-Sialoglycoproteins,
pubmed-meshheading:8670316-Treatment Outcome
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.
|
|
pubmed:affiliation |
Synergen Inc., Boulder, Colorado, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
